Dr. Kobayashi is Partner of Amplify and Head of Therapeutics at Mass General Brigham (MGB) Innovation, where she manages the pre-commercial fund and team and invests in and operates pre-companies and newcos, including in neuroscience. She has extensive experience in translational drug development and company creation within the central nervous system (CNS) field, and has previously served as Vice President of Preclinical Translation at Cydan Development and held director roles at the neurodegeneration companies Alector and Annexon, as well as at the Spinal Muscular Atrophy Foundation. Earlier in her career she spent around ten years as a scientist and research program leader at Genentech, Elan and Pfizer. She has launched or co-founded several companies in CNS, gene therapy and rare disease. Dr. Kobayashi holds a PhD in neuroscience from the University of Edinburgh and an undergraduate degree from MIT.
Read more here